Case Study

How Optina Diagnostics Uses Castor EDC In Research Of Earlier Disease Detection

Source: Castor
GettyImages-1443965506 doctor clinical trial data monitoring

Experts estimate that nearly half of individuals living with dementia remain undiagnosed. Detecting the disease earlier could significantly enhance the quality of life for both patients and caregivers, in addition to potentially saving the US healthcare system billions of dollars. With the paramount objective of early disease detection, Optina Diagnostics is spearheading the development of a groundbreaking solution.

At the core of their innovation lies a sophisticated combination of a hyperspectral camera and artificial intelligence (AI). This pioneering technology aims to identify early signs of Alzheimer’s disease directly through the eye. By leveraging the unique capabilities of hyperspectral imaging and AI-driven analysis, Optina Diagnostics seeks to revolutionize the diagnostic process for Alzheimer’s, offering hope for earlier intervention and improved outcomes for those affected by the disease.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader